High Prevalence of Multidrug-Resistant Clostridioides difficile Following Extensive Use of Antimicrobials in Hospitalized Patients in Kenya

Introduction Clostridioides difficile is a neglected pathogen in many African countries as it is generally not regarded as one of the major contributors toward the diarrheal disease burden in the continent. However, several studies have suggested that C. difficile infection (CDI) may be underreported in many African settings. The aim of this study was to determine the prevalence of CDI in hospitalized patients, evaluate antimicrobial exposure, and detect toxin and antimicrobial resistance profiles of the isolated C. difficile strains. Methods In this cross-sectional study, 333 hospitalized patients with hospital-onset diarrhoea were selected. The stool samples were collected and cultured on cycloserine-cefoxitin egg yolk agar (CCEY). Isolates were presumptively identified by phenotypic characteristics and Gram stain and confirmed by singleplex real-time PCR (qPCR) assays detecting the species-specific tpi gene, toxin A (tcdA) gene, toxin B (tcdB) gene, and the binary toxin (cdtA/cdtB) genes. Confirmed C. difficile isolates were tested against a panel of eight antimicrobials (vancomycin, metronidazole, rifampicin, ciprofloxacin, tetracycline, clindamycin, erythromycin, and ceftriaxone) using E-test strips. Results C. difficile was detected in 57 (25%) of diarrheal patients over the age of two, 56 (98.2%) of whom received antimicrobials before the diarrheal episode. Amongst the 71 confirmed isolates, 69 (97.1%) harbored at least one toxin gene. More than half of the toxigenic isolates harbored a truncated tcdA gene. All isolates were sensitive to vancomycin, while three isolates (2.1%) were resistant to metronidazole (MIC >32 mg/L). High levels of resistance were observed to rifampicin (65/71, 91.5%), erythromycin (63/71, 88.7%), ciprofloxacin (59/71, 83.1%), clindamycin (57/71, 80.3%), and ceftriaxone (36/71, 50.7.8%). Among the resistant isolates, 61 (85.9%) were multidrug-resistant. Conclusion Multidrug-resistant C. difficile strains were a significant cause of healthcare facility-onset C. difficile infections in patients with prior antimicrobial exposure in this Kenyan hospital.

[1]  A. Gikas,et al.  Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis , 2020, PloS one.

[2]  R. Prasad,et al.  Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives , 2020, HIV/AIDS.

[3]  O. Lund,et al.  Ceftriaxone use in a tertiary care hospital in Kilimanjaro, Tanzania: A need for a hospital antibiotic stewardship programme , 2019, PloS one.

[4]  B. Godman,et al.  Antibiotic Prescribing Patterns at a Leading Referral Hospital in Kenya: A Point Prevalence Survey , 2019, Journal of research in pharmacy practice.

[5]  E. Kuijper,et al.  Plasmid-mediated metronidazole resistance in Clostridioides difficile , 2019, Nature Communications.

[6]  Kimberly Plants-Paris,et al.  Prevalence of Clostridium difficile infections among Kenyan children with diarrhea. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[7]  Ziyong Sun,et al.  Epidemiology of Clostridium difficile infection in hospitalized adults and the first isolation of C. difficile PCR ribotype 027 in central China , 2019, BMC Infectious Diseases.

[8]  P. Kiratisin,et al.  Clostridium difficile ribotype 017 – characterization, evolution and epidemiology of the dominant strain in Asia , 2019, Emerging microbes & infections.

[9]  K. Kasera,et al.  Kenya tuberculosis prevalence survey 2016: Challenges and opportunities of ending TB in Kenya , 2018, PloS one.

[10]  M. Azimirad,et al.  Prevalence of binary-toxin genes (cdtA and cdtB) among clinical strains of Clostridium difficile isolated from diarrheal patients in Iran , 2018, Gastroenterology and hepatology from bed to bench.

[11]  V. Abratt,et al.  Clostridium difficile in patients attending tuberculosis hospitals in Cape Town, South Africa, 2014–2015 , 2018, African journal of laboratory medicine.

[12]  M. Kirk,et al.  Modelling diverse sources of Clostridium difficile in the community: importance of animals, infants and asymptomatic carriers , 2018, Epidemiology and Infection.

[13]  R. Carman,et al.  Multidrug resistant Clostridium difficile ribotype 027 in southwestern Virginia, 2007 to 2013. , 2018, Anaerobe.

[14]  H. Dupont,et al.  High rate of Clostridium difficile among young adults presenting with diarrhea at two hospitals in Kenya , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[15]  Herman Goossens,et al.  Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. , 2018, The Lancet. Global health.

[16]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Akoachere,et al.  Prescribing patterns and associated factors of antibiotic prescription in primary health care facilities of Kumbo East and Kumbo West Health Districts, North West Cameroon , 2018, PloS one.

[18]  N. Pollock,et al.  Assessing the Burden of Clostridium difficile Infection in Low- and Middle-Income Countries , 2018, Journal of Clinical Microbiology.

[19]  P. Kiratisin,et al.  Antimicrobial susceptibility of Clostridium difficile isolated in Thailand , 2017, Antimicrobial Resistance & Infection Control.

[20]  C. Stratton,et al.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing , 2017, Journal of Clinical Microbiology.

[21]  N. Thomson,et al.  A Clostridium difficile Lineage Endemic to Costa Rican Hospitals Is Multidrug Resistant by Acquisition of Chromosomal Mutations and Novel Mobile Genetic Elements , 2017, Antimicrobial Agents and Chemotherapy.

[22]  Jieun Kim,et al.  Clinical Characteristics and Treatment Outcomes of Clostridium difficile Infections by PCR Ribotype 017 and 018 Strains , 2016, PloS one.

[23]  M. Rupnik,et al.  High prevalence of nontoxigenic Clostridium difficile isolated from hospitalized and non-hospitalized individuals in rural Ghana. , 2016, International journal of medical microbiology : IJMM.

[24]  P. Lawson,et al.  Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. , 2016, Anaerobe.

[25]  N. Minton,et al.  Improving the reproducibility of the NAP1/B1/027 epidemic strain R20291 in the hamster model of infection , 2016, Anaerobe.

[26]  N. Beeching,et al.  Clostridium difficile: A healthcare-associated infection of unknown significance in adults in sub-Saharan Africa. , 2016, Malawi medical journal : the journal of Medical Association of Malawi.

[27]  S. Bird,et al.  Extensive antibiotic prescription rate among hospitalized patients in Uganda: but with frequent missed-dose days , 2016, The Journal of antimicrobial chemotherapy.

[28]  P. Spigaglia,et al.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection , 2016, Therapeutic advances in infectious disease.

[29]  O. Nyč,et al.  Antibiotic profiling of Clostridium difficile ribotype 176--A multidrug resistant relative to C. difficile ribotype 027. , 2015, Anaerobe.

[30]  D. Paterson,et al.  Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications , 2015, BMC Infectious Diseases.

[31]  D. Gerding,et al.  Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027 , 2015, Antimicrobial Agents and Chemotherapy.

[32]  O. Zimmermann,et al.  Clostridium difficile infections among adults and children in Mwanza/Tanzania: is it an underappreciated pathogen among immunocompromised patients in sub-Saharan Africa? , 2015, New microbes and new infections.

[33]  T. Dubois,et al.  Clostridium difficile: New Insights into the Evolution of the Pathogenicity Locus , 2015, Scientific Reports.

[34]  A. Roberts,et al.  Mobile genetic elements in Clostridium difficile and their role in genome function , 2015, Research in microbiology.

[35]  V. Abratt,et al.  Prevalence of gastrointestinal pathogenic bacteria in patients with diarrhoea attending Groote Schuur Hospital, Cape Town, South Africa. , 2015, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[36]  P. Mastrantonio,et al.  Fluoroquinolone Resistance Does Not Impose a Cost on the Fitness of Clostridium difficile In Vitro , 2014, Antimicrobial Agents and Chemotherapy.

[37]  B. Weimer,et al.  Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. , 2014, Cell host & microbe.

[38]  L. Bebell,et al.  Antibiotic use and emerging resistance: how can resource-limited countries turn the tide? , 2014, Global heart.

[39]  E. Kuijper,et al.  Occurrence of Clostridium difficile PCR-ribotype 027 and it's closely related PCR-ribotype 176 in hospitals in Poland in 2008-2010. , 2014, Anaerobe.

[40]  A. Moya,et al.  Structural and functional changes in the gut microbiota associated to Clostridium difficile infection , 2014, Front. Microbiol..

[41]  C. Simango,et al.  Detection of Clostridium difficile diarrhoea in Harare, Zimbabwe. , 2014, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[42]  T. Riley,et al.  Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.

[43]  Mark A. Miller,et al.  Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole , 2014, PloS one.

[44]  D. Gerding,et al.  Clostridium difficile binary toxin CDT , 2013, Gut microbes.

[45]  R. P. Ross,et al.  Analysis of Anti-Clostridium difficile Activity of Thuricin CD, Vancomycin, Metronidazole, Ramoplanin, and Actagardine, both Singly and in Paired Combinations , 2013, Antimicrobial Agents and Chemotherapy.

[46]  E. Kuijper,et al.  Antimicrobial susceptibility profiles of human and piglet Clostridium difficile PCR-ribotype 078 , 2013, Antimicrobial Resistance and Infection Control.

[47]  M. Mendelson,et al.  The Clostridium difficile problem: a South African tertiary institution's prospective perspective. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[48]  M. Pirmohamed,et al.  Emergence and global spread of epidemic healthcare-associated Clostridium difficile , 2012, Nature Genetics.

[49]  A. Le Monnier,et al.  Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  F. Tenover,et al.  Antimicrobial-Resistant Strains of Clostridium difficile from North America , 2012, Antimicrobial Agents and Chemotherapy.

[51]  A. Goorhuis,et al.  Type-specific risk factors and outcome in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  C. Ukomadu,et al.  High prevalence of toxinogenic Clostridium difficile in Nigerian adult HIV patients. , 2011, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[53]  Fabrizio Barbanti,et al.  Multidrug resistance in European Clostridium difficile clinical isolates. , 2011, The Journal of antimicrobial chemotherapy.

[54]  M. Rupnik,et al.  New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. , 2011, Journal of medical microbiology.

[55]  W. Moon,et al.  Development of Pseudomembranous Colitis Four Months after Initiation of Rifampicin , 2011, Case Reports in Gastroenterology.

[56]  M. Rupnik,et al.  Clostridium difficile toxinotype XI (A-B-) exhibits unique arrangement of PaLoc and its upstream region. , 2010, Anaerobe.

[57]  M. Quail,et al.  Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium , 2009, Genome Biology.

[58]  J. Bartlett,et al.  Clinical recognition and diagnosis of Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  J. Lemeland,et al.  Multiplex PCR Targeting tpi (Triose Phosphate Isomerase), tcdA (Toxin A), and tcdB (Toxin B) Genes for Toxigenic Culture of Clostridium difficile , 2004, Journal of Clinical Microbiology.

[60]  Hiroko Sato,et al.  [A nosocomial outbreak of diarrhea caused by toxin A-negative, toxin B-positive Clostridium difficile in a cancer center hospital]. , 2004, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[61]  D. Gerding.  Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  Z. Samra,et al.  High prevalence of toxin A-negative toxin B-positive Clostridium difficile in hospitalized patients with gastrointestinal disease. , 2002, Diagnostic microbiology and infectious disease.

[63]  E. Kuijper,et al.  Nosocomial Outbreak of Clostridium difficile-Associated Diarrhoea due to a Clindamycin-Resistant Enterotoxin A-Negative Strain , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[64]  J. Mwansa,et al.  Contrasting incidence of Clostridium difficile and other enteropathogens in AIDS patients in London and Lusaka. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[65]  M. Alfa,et al.  An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. , 1999, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[66]  J. Paul,et al.  Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya , 1998, Journal of Infection.

[67]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  S. Fanning,et al.  Isolation and Characterization of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland , 2017 .

[69]  Guang-xi Li,et al.  Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .